Liver Limitations in post-marketing surveillance and public reporting in the USA, particularly in the 1980s, largely accounted for delays in ensuring an appropriate response to pemo-line hepatotoxicity (56R). Several authors have urged that voluntary reporting systems need augmentation (57R, 58r, 59R), including the addition of an active surveillance system to assess the prevalence of adverse drug reactions and the increased use of public health-oriented information sources to disseminate clearly documented drug risk information to physicians and their patients. The case of pemoline is just one example of this.
DRUGS USED IN ALZHEIMER'S DISEASE (SED-14, 435; SEDA-23, 8; SEDA-24, 6; SEDA-25, 7)
Cholinesterase inhibitors are currently the mainstay of treatment for mild-to-moderate
Was this article helpful?
The comprehensive new ebook All About Alzheimers puts everything into perspective. Youll gain insight and awareness into the disease. Learn how to maintain the patients emotional health. Discover tactics you can use to deal with constant life changes. Find out how counselors can help, and when they should intervene. Learn safety precautions that can protect you, your family and your loved one. All About Alzheimers will truly empower you.